Analysis of clinical characteristics and outcomes of ALK positive (ALK plus ) patients treated with ALK inhibitors (ALKi).

被引：0
|
作者：
Perez, Susana Cedres
Aranda, Nuria Pardo
Navarro, Alejandro
Marti, Alex Martinez
de Castro, Ana Maria Martinez
Cabrera, Guadalupe
Vilaro, Marta
Carbonell, LLuisa
de la Fuente, Iris
Piera, Adelaida
Martinez, Lidia
Hernandez-Losa, Javier
Sansano, Irene
Felip, Enriqueta
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[4] Inst Salvadoreno Seguro Social, San Salvador, El Salvador
[5] Vall dHebron Inst Oncol, Oncol Data Sci OdysSey Grp, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[7] Vall dHebron Univ, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20550
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
    Yang, Dafu
    Li, Dan
    Dai, Zhaoxia
    Ma, Yutong
    Ou, Qiuxiang
    Wu, Xue
    Cui, Saiqiong
    CANCER COMMUNICATIONS, 2021, 41 (02) : 183 - 186
  • [12] Description of ALK plus NSCLC patient characteristics and ALK testing patterns
    Wakelee, Heather A.
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip J.
    Jarvis, John
    Kageletry, Andrew James
    Huang, Qing
    Culver, Kenneth W.
    Wu, Eric Qiong
    Guerin, Annie
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [13] Description of ALK plus NSCLC Patient Characteristics and ALK Testing Patterns
    Wakelee, H. A.
    Sasane, M.
    Zhang, J.
    Macalalad, A. R.
    Galebach, P.
    Jarvis, J.
    Kageleiry, A.
    Huang, Q.
    Culver, K.
    Wu, E. Q.
    Guerin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S60 - S61
  • [14] Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer.
    Murakami, Haruyasu
    Ono, Akira
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [15] EPIDEMIOLOGICAL, CLINICAL AND HUMANISTIC BURDEN AMONG ALK plus NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) PATIENTS TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)
    Pan, X.
    Kwon, C. S.
    Garib, S. A.
    Forsythe, A.
    Lin, H. M.
    VALUE IN HEALTH, 2019, 22 : S56 - S56
  • [16] Background of patients (pts) with ALK rearranged (ALK plus ) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study
    Ito, K.
    Saiki, H.
    Sakaguchi, T.
    Hayashi, K.
    Nishii, Y.
    Watanabe, F.
    Hataji, O.
    Okano, T.
    Naito, M.
    Ibata, H.
    Fujiwara, A.
    Yoshida, M.
    Itani, H.
    Tanigawa, M.
    Kobayashi, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [17] Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
    Damm-Welk, Christine
    Siddiqi, Faraz
    Fischer, Matthias
    Hero, Barbara
    Narayanan, Vignesh
    Camidge, David Ross
    Harris, Michael
    Burke, Amos
    Lehrnbecher, Thomas
    Pulford, Karen
    Oschlies, Ilske
    Siebert, Reiner
    Turner, Suzanne
    Woessmann, Wilhelm
    JOURNAL OF CANCER, 2016, 7 (11): : 1383 - 1387
  • [18] Sequencing of ALK Inhibitors in ALK plus Non-Small Cell Lung Cancer
    Gadgeel, Shirish M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [19] PROs with Ceritinib in ALKi-Naive ALK plus NSCLC Patients with and without Brain Metastases
    Park, Keunchil
    Felip, Enriqueta
    Orlov, Sergey
    Yu, Chong-Jen
    Tsai, Chun-Ming
    Nishio, Makoto
    Dols, Manuel Cobo
    Mckeage, Mark
    Su, Wu-Chou
    Mok, Tony
    Scagliotti, Giorgio V. V.
    Spigel, David R.
    Zhang, Jie
    Branle, Fabrice
    Emeremni, Chetachi
    Sutradhar, Santosh
    Quadrigli, Massimiliano
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S379 - S380
  • [20] Characteristics and treatment patterns of ALK plus NSCLC patients who receive second-generation ALK inhibitors: A chart review study
    Cadranel, J.
    Park, K.
    Pless, M.
    Bendaly, E.
    Patel, D.
    Sasane, M.
    Swallow, E.
    Galebach, P.
    Stein, K.
    Marinsek, N.
    Zhang, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S627 - S628
12345